4.5 Review

Modulating Self-Assembly of Amyloidogenic Proteins as a Therapeutic Approach for Neurodegenerative Diseases: Strategies and Mechanisms

期刊

CHEMMEDCHEM
卷 7, 期 3, 页码 359-374

出版社

WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.201100585

关键词

aggregation; amyloid proteins; drug design; inhibitors; molecular tweezers; oligomerization; polyphenols

资金

  1. University of California, Los Angeles (UCLA) Jim Easton Consortium for Alzheimer's Drug Discovery and Biomarker Development
  2. California Department of Health Services (USA) [07-65798]
  3. Team Parkinson/Parkinson Alliance (Kingston, USA)
  4. RJG Foundation (New York, USA) [20095024]
  5. Cure Alzheimer's Fund (USA)

向作者/读者索取更多资源

Abnormal protein assembly causes multiple devastating disorders in the central nervous system (CNS), such as Alzheimers, Parkinsons, Huntingtons, and prion diseases. Due to the now extended human lifespan, these diseases have been increasing in prevalence, resulting in major public health problems and the associated financial difficulties worldwide. The wayward proteins that lead to disease self-associate into neurotoxic oligomers and go on to form fibrillar polymers through multiple pathways. Thus, a range of possible targets for pharmacotherapeutic intervention exists along these pathways. Many compounds have shown different levels of effectiveness in inhibiting aberrant self-assembly, dissociating existing aggregates, protecting cells against neurotoxic insults, and in some cases ameliorating disease symptoms in vivo, yet achieving efficient, disease-modifying therapy in humans remains a major unattained goal. To a large degree, this is because the mechanisms of action for these drugs are essentially unknown. For successful design of new effective drugs, it is crucial to elucidate the mechanistic details of their action, including the actual target(s) along the protein aggregation pathways, how the compounds modulate these pathways, and their effect at the cellular, tissue, organ, and organism level. Here, the current knowledge of major mechanisms by which some of the more extensively explored drug candidates work are discussed. In particular, we focus on three prominent strategies: 1) stabilizing the native fold of amyloidogenic proteins, 2) accelerating the aggregation pathways towards the fibrillar endpoint thereby reducing accumulation of toxic oligomers, and 3) modulating the assembly process towards nontoxic oligomers/aggregates. The merit of each strategy is assessed, and the key points to consider when analyzing the efficacy of possible drug candidates and their mechanism of action are discussed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Clinical Neurology

The molecular tweezer CLR01 improves behavioral deficits and reduces tau pathology in P301S-tau transgenic mice

Jing Di, Ibrar Siddique, Zizheng Li, Ghattas Malki, Simon Hornung, Suman Dutta, Ian Hurst, Ella Ishaaya, Austin Wang, Sally Tu, Ani Boghos, Ida Ericsson, Frank-Gerrit Klaerner, Thomas Schrader, Gal Bitan

Summary: The study demonstrated that CLR01 directly targets tau protein to ameliorate Alzheimer's disease pathology. However, limitations of the study, such as a relatively short treatment period and high variability in the model, lowered the statistical significance of some outcomes.

ALZHEIMERS RESEARCH & THERAPY (2021)

Article Clinical Neurology

α-Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson's disease from multiple system atrophy

Suman Dutta, Simon Hornung, Adira Kruayatidee, Katherine N. Maina, Irish del Rosario, Kimberly C. Paul, Darice Y. Wong, Aline Duarte Folle, Daniela Markovic, Jose-Alberto Palma, Geidy E. Serrano, Charles H. Adler, Susan L. Perlman, Wayne W. Poon, Un Jung Kang, Roy N. Alcalay, Miriam Sklerov, Karen H. Gylys, Horacio Kaufmann, Brent L. Fogel, Jeff M. Bronstein, Beate Ritz, Gal Bitan

Summary: The study found that measuring α-syn in exosomes from blood can effectively distinguish between patients with PD and MSA with high sensitivity and specificity. A multinomial logistic model combining α-syn concentration, exosome concentration, and a ratio between α-syn concentrations in specific exosomes showed promising results in separating PD from MSA.

ACTA NEUROPATHOLOGICA (2021)

Correction Clinical Neurology

α-Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson's disease from multiple system atrophy (May, 10.1007/s00401-021-02324-0, 2021)

Suman Dutta, Simon Hornung, Adira Kruayatidee, Katherine N. Maina, Irish del Rosario, Kimberly C. Paul, Darice Y. Wong, Aline Duarte Folle, Daniela Markovic, Jose-Alberto Palma, Geidy E. Serrano, Charles H. Adler, Susan L. Perlman, Wayne W. Poon, Un Jung Kang, Roy N. Alcalay, Miriam Sklerov, Karen H. Gylys, Horacio Kaufmann, Brent L. Fogel, Jeff M. Bronstein, Beate Ritz, Gal Bitan

Summary: A correction to the paper has been published.

ACTA NEUROPATHOLOGICA (2021)

Review Biochemistry & Molecular Biology

Aptamers targeting amyloidogenic proteins and their emerging role in neurodegenerative diseases

Kazuma Murakami, Naotaka Izuo, Gal Bitan

Summary: Aptamers, similar to antibodies, are oligonucleotides selected based on their affinity for bioactive molecules. They have advantages such as small size, easy synthesis, high stability, and low immunogenicity. However, developing aptamers against amyloidogenic proteins, which are relevant to neurodegenerative diseases, is challenging due to their conformational instability and heterogeneity. Recent advancements in chemical tethering of aptagens, high-throughput sequencing-based analysis, and internalization technologies have helped overcome some of these challenges. This review highlights the preclinical application of antiamyloid aptamers to central nervous system therapy.

JOURNAL OF BIOLOGICAL CHEMISTRY (2022)

Article Clinical Neurology

mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double-Blind, Placebo-Controlled Futility Trial and 1-Year Biomarker Longitudinal Analysis

Jose-Alberto Palma, Jose Martinez, Patricio Millar Vernetti, Thong Ma, Miguel A. Perez, Judy Zhong, Yingzhi Qian, Suman Dutta, Katherine N. Maina, Ibrar Siddique, Gal Bitan, Benjamin Ades-Aron, Timothy M. Shepherd, Un J. Kang, Horacio Kaufmann

Summary: The efficacy and safety of sirolimus in patients with multiple system atrophy (MSA) were investigated in this study. The results showed that sirolimus treatment for 48 weeks was futile in slowing the progression of MSA and had no effect on biomarkers compared to placebo. Changes in blood neurofilament light chain (NfL) and whole brain atrophy were identified as promising biomarkers of disease progression for future clinical trials.

MOVEMENT DISORDERS (2022)

Article Biochemistry & Molecular Biology

Three-repeat and four-repeat tau isoforms form different oligomers

Hedieh Shahpasand-Kroner, Jennifer Portillo, Carter Lantz, Paul M. Seidler, Natalie Sarafian, Joseph A. Loo, Gal Bitan

Summary: This study analyzed the initial oligomerization of six tau isoforms in the absence of posttranslational modifications or other manipulations. The results showed that three-repeat (3R) isoforms are more prone to form oligomers than four-repeat (4R) isoforms. Known tau aggregation inhibitors had little or no effect on the initial oligomerization.

PROTEIN SCIENCE (2022)

Correction Biochemistry & Molecular Biology

Comparison of Three Amyloid Assembly Inhibitors: The Sugar scyllo-Inositol, the Polyphenol Epigallocatechin Gallate, and the Molecular Tweezer CLR01 (vol 3, pg 451, 2012)

Sharmistha Sinha, Zhenming Du, Panchanan Maiti, Frank-Gerrit Klarner, Thomas Schrader, Chunyu Wang, Gal Bitan

ACS CHEMICAL NEUROSCIENCE (2022)

Editorial Material Neurosciences

A minute fraction of α-synuclein in extracellular vesicles may be a major contributor to α-synuclein spreading following autophagy inhibition

Hash Brown Taha, Brian Kearney, Gal Bitan

FRONTIERS IN MOLECULAR NEUROSCIENCE (2022)

Article Biochemistry & Molecular Biology

Development of a Novel Electrochemiluminescence ELISA for Quantification of ?-Synuclein Phosphorylated at Ser129 in Biological Samples

Suman Dutta, Simon Hornung, Hash Brown Taha, Karl Biggs, Ibrar Siddique, Lea M. Chamoun, Hedieh Shahpasand-Kroner, Carter Lantz, Marcos Herrera-Vaquero, Nadia Stefanova, Joseph A. Loo, Gal Bitan

Summary: A new method for sensitive detection of pS129-alpha-syn has been developed, which can be applied to various biological samples. This method provides a valuable tool for discovering and monitoring neurodegenerative diseases associated with abnormal accumulation of synaptic proteins.

ACS CHEMICAL NEUROSCIENCE (2023)

Review Clinical Neurology

Biomarkers for parkinsonian disorders in CNS-originating EVs: promise and challenges

Suman Dutta, Simon Hornung, Hash Brown Taha, Gal Bitan

Summary: Extracellular vesicles (EVs) are small particles enclosed by a lipid bilayer, which play a role in intercellular communication by transporting various biomaterials. In neurodegenerative diseases, EVs may carry toxic proteins and facilitate their spread in the central nervous system. These EVs can be found in body fluids like saliva, tears, and urine, making them a potential source of biomarkers. Despite the progress in utilizing CNS-originating EVs for biomarker studies, certain technical challenges, such as isolating cell type-specific EVs and validating their origin, still need to be addressed.

ACTA NEUROPATHOLOGICA (2023)

Editorial Material Geriatrics & Gerontology

Editorial: Trends in biomarkers for neurodegenerative diseases: Current research and future perspectives

Suman Dutta, Miriam Sklerov, Charlotte E. Teunissen, Gal Bitan

FRONTIERS IN AGING NEUROSCIENCE (2023)

Letter Neurosciences

Toward a biomarker panel measured in CNS-originating extracellular vesicles for improved differential diagnosis of Parkinson's disease and multiple system atrophy

Hash Brown Taha, Simon Hornung, Suman Dutta, Leony Fenwick, Otmane Lahgui, Kathryn Howe, Nour Elabed, Irish del Rosario, Darice Y. Y. Wong, Aline Duarte Folle, Daniela Markovic, Jose-Alberto Palma, Un Jung Kang, Roy N. N. Alcalay, Miriam Sklerov, Horacio Kaufmann, Brent L. L. Fogel, Jeff M. M. Bronstein, Beate Ritz, Gal Bitan

TRANSLATIONAL NEURODEGENERATION (2023)

Meeting Abstract Biochemistry & Molecular Biology

The molecular tweezer CLR01 reduces motor impairments and neuropathology in spinocerebellar ataxia type 3 in vivo models

Daniela Vilasboas-Campos, Sara Duarte-Silva, Daniela Monteiro-Fernandes, Joana Pereira-Sousa, Andreia Neves-Carvalho, Gal Bitan, Sandra Macedo-Ribeiro, Alexandra Silva, Ana Luisa Carvalho, Andreia Teixeira-Castro, Patricia Maciel

JOURNAL OF NEUROCHEMISTRY (2022)

Correction Biochemistry & Molecular Biology

Surprising toxicity and assembly behaviour of amyloid β-protein oxidized to sulfone (vol 433, pg 323, 2011)

Panchanan Maiti, Roberto Piacentini, Cristian Ripoli, Claudio Grassi, Gal Bitan

BIOCHEMICAL JOURNAL (2021)

Article Biochemistry & Molecular Biology

Inhibition of Staphylococcus aureus biofilm-forming functional amyloid by molecular tweezers

Ravit Malishev, Nir Salinas, James Gibson, Angela Bailey Eden, Joel Mieres-Perez, Yasser B. Ruiz-Blanco, Orit Malka, Sofiya Kolusheva, Frank-Gerrit Klaemer, Thomas Schrader, Elsa Sanchez-Garcia, Chunyu Wang, Meytal Landau, Gal Bitan, Raz Jelinek

Summary: This study demonstrates that molecular tweezers can modulate biofilm formation of Staphylococcus aureus, with CLR01 significantly inhibiting biofilm formation and disrupting PSM alpha 1 assembly, while CLR05, containing methylenecarboxylate units, disrupts biofilm more strongly despite lower lysine residues affinity. Molecular tweezers may serve as potent biofilm inhibitors and antibacterial agents against bacteria producing biofilms and PSM.

CELL CHEMICAL BIOLOGY (2021)

暂无数据